McIlrath & Eck’s Avita Medical RCEL Stock Holding History

McIlrath & Eck’s Portfolio RCEL Stock Details RCEL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-100	Closed	-$529	–	973
2025 Q2	$529	Buy	+100	New	+$727	﹤0.01%	898

Other funds holding RCEL

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

DSCM

Divisadero Street Capital Management Miami, Florida $2.39B AUM 134.55% 1-Year Est. Return

McIlrath & Eck's RCEL Position: Q3 2025 in Review

McIlrath & Eck sold out of Avita Medical (RCEL) in Q3 2025, closing a stake of 100 shares — an estimated $529 sold.

McIlrath & Eck first reported a position in RCEL in Q2 2025 and held it in 1 quarter. The position peaked at $529 in Q2 2025. 76 funds tracked by Wall St. Rank hold RCEL as of Q3 2025.

McIlrath & Eck reported no remaining Avita Medical position as of Q3 2025 after selling out during the quarter.
McIlrath & Eck sold 100 Avita Medical shares in Q3 2025, an estimated $529.
McIlrath & Eck first reported a position in Avita Medical in Q2 2025 and held it in 1 quarter.
McIlrath & Eck's Avita Medical position peaked at $529 in Q2 2025.
76 funds tracked by Wall St. Rank held Avita Medical as of Q3 2025.

Based on McIlrath & Eck's 13F filing for Q3 2025, filed 22 Oct 2025.